Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells

BMC Complementary and Alternative Medicine

Volumn 11, Issue , 2011, Pages

  Suhail, Mahmoud M ^a   Wu, Weijuan ^b   Cao, Amy ^c   Mondalek, Fadee G ^b   Fung, Kar Ming ^b   Shih, Pin Tsen ^b,d   Fang, Yu Ting ^b,d   Woolley, Cole ^e   Young, Gary ^e   Lin, Hsueh Kung ^b  

^a Al Afia Medical Complex   (Oman)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e Young Living Essential Oils   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BOSWELLIA SACRA EXTRACT; BOSWELLIC ACID; CASPASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; ESSENTIAL OIL; GENOMIC DNA; PLANT EXTRACT; PROTEIN KINASE B; RESIN; UNCLASSIFIED DRUG; VEGETABLE OIL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BOSWELLIA; BOSWELLIA SACRA; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE REGULATION; CELL STRAIN MCF 7; CELL VIABILITY; CHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDRODISTILLATION; IC 50; MASS SPECTROMETRY; MOLECULAR WEIGHT; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SPHEROID CELL; TUMOR CELL; WESTERN BLOTTING; BLADDER TUMOR; CANCER INVASION; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; MASS FRAGMENTOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; BOSWELLIA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; NEOPLASM INVASIVENESS; OILS, VOLATILE; PLANT OILS; URINARY BLADDER NEOPLASMS;

EID: 83455213613     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-11-129     Document Type: Article

References (71)

1. Maloney GA. Gold, frankincense, and myrrh : an introduction to Eastern Christian spirituality. 1997, New York: Crossroads Pub. Co.
2. Banno N, Akihisa T, Yasukawa K, Tokuda H, Tabata K, Nakamura Y, Nishimura R, Kimura Y, Suzuki T. Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J Ethnopharmacol 2006, 107:249-253. 10.1016/j.jep.2006.03.006, 16621377.
3. Langmead L, Rampton DS. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006, 23:341-349. 10.1111/j.1365-2036.2006.02761.x, 16422993.
4. Chevrier MR, Ryan AE, Lee DY, Zhongze M, Wu-Yan Z, Via CS. Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. Clin Diagn Lab Immunol 2005, 12:575-580. 1112084, 15879017.
5. Sharma ML, Khajuria A, Kaul A, Singh S, Singh GB, Atal CK. Effect of salai guggal ex-Boswellia serrata on cellular and humoral immune responses and leucocyte migration. Agents Actions 1988, 24:161-164. 10.1007/BF01968095, 3407547.
6. Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 1986, 18:407-412. 10.1007/BF01965005, 3751752.
7. Weckesser S, Engel K, Simon-Haarhaus B, Wittmer A, Pelz K, Schempp CM. Screening of plant extracts for antimicrobial activity against bacteria and yeasts with dermatological relevance. Phytomedicine 2007, 14:508-516. 10.1016/j.phymed.2006.12.013, 17291738.
8. Huang MT, Badmaev V, Ding Y, Liu Y, Xie JG, Ho CT. Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid. Biofactors 2000, 13:225-230. 10.1002/biof.5520130135, 11237186.
9. Winking M, Sarikaya S, Rahmanian A, Jodicke A, Boker DK. Boswellic acids inhibit glioma growth: a new treatment option?. J Neurooncol 2000, 46:97-103. 10.1023/A:1006387010528, 10894362.
10. Hostanska K, Daum G, Saller R. Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro. Anticancer Res 2002, 22:2853-2862.
11. Flavin DF. A lipoxygenase inhibitor in breast cancer brain metastases. J Neurooncol 2007, 82:91-93. 10.1007/s11060-006-9248-4, 17001517.
12. Akihisa T, Tabata K, Banno N, Tokuda H, Nishimura R, Nakamura Y, Kimura Y, Yasukawa K, Suzuki T. Cancer chemopreventive effects and cytotoxic activities of the triterpene acids from the resin of Boswellia carteri. Biol Pharm Bull 2006, 29:1976-1979. 10.1248/bpb.29.1976, 16946522.
13. Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol 1995, 47:1212-1216.
14. Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Muller S, Senninger N, Russell J, Jauch J, Bergmann J, et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2006, 290:G1131-1137. 10.1152/ajpgi.00562.2005, 16423918.
15. Park YS, Lee JH, Bondar J, Harwalkar JA, Safayhi H, Golubic M. Cytotoxic action of acetyl-11-keto-β-boswellic acid (AKBA) on meningioma cells. Planta Med 2002, 68:397-401. 10.1055/s-2002-32090, 12058313.
16. Shao Y, Ho CT, Chin CK, Badmaev V, Ma W, Huang MT. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med 1998, 64:328-331. 10.1055/s-2006-957444, 9619114.
17. Liu JJ, Nilsson A, Oredsson S, Badmaev V, Duan RD. Keto- and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. Int J Mol Med 2002, 10:501-505.
18. Zhao W, Entschladen F, Liu H, Niggemann B, Fang Q, Zaenker KS, Han R. Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detect Prev 2003, 27:67-75. 10.1016/S0361-090X(02)00170-8, 12600419.
19. Liu JJ, Nilsson A, Oredsson S, Badmaev V, Zhao WZ, Duan RD. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 2002, 23:2087-2093. 10.1093/carcin/23.12.2087, 12507932.
20. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M. Acetyl-11-keto-b-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 2009, 69:5893-5900. 10.1158/0008-5472.CAN-09-0755, 2724674, 19567671.
21. Lu M, Xia L, Hua H, Jing Y. Acetyl-keto-β-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer Res 2008, 68:1180-1186. 10.1158/0008-5472.CAN-07-2978, 18281494.
22. Syrovets T, Gschwend JE, Buchele B, Laumonnier Y, Zugmaier W, Genze F, Simmet T. Inhibition of IκB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 2005, 280:6170-6180.
23. Mikhaeil BR, Maatooq GT, Badria FA, Amer MM. Chemistry and immunomodulatory activity of frankincense oil. Z Naturforsch C 2003, 58:230-238.
24. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 1979, 15:659-670. 10.1016/0014-2964(79)90139-7, 228940.
25. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973, 51:1409-1416.
26. Cailleau R, Young R, Olive M, Reeves WJ. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974, 53:661-674.
27. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990, 50:6075-6086.
28. Yang Q, Titus MA, Fung KM, Lin HK. 5α-androstane-3α,17β-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression. J Cell Biochem 2008, 104:1612-1624. 10.1002/jcb.21731, 18320593.
29. Mondalek FG, Lawrence BJ, Kropp BP, Grady BP, Fung KM, Madihally SV, Lin HK. The incorporation of poly(lactic-co-glycolic) acid nanoparticles into porcine small intestinal submucosa biomaterials. Biomaterials 2008, 29:1159-1166. 10.1016/j.biomaterials.2007.11.020, 2947939, 18076986.
30. Sasaki CY, Passaniti A. Identification of anti-invasive but noncytotoxic chemotherapeutic agents using the tetrazolium dye MTT to quantitate viable cells in Matrigel. Biotechniques 1998, 24:1038-1043.
31. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592. 10.1038/nrc1893, 16862189.
32. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992, 356:356-358. 10.1038/356356a0, 1549180.
33. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998, 273:33533-33539. 10.1074/jbc.273.50.33533, 9837934.
34. Buchele B, Zugmaier W, Estrada A, Genze F, Syrovets T, Paetz C, Schneider B, Simmet T. Characterization of 3α-acetyl-11-keto-α-boswellic acid, a pentacyclic triterpenoid inducing apoptosis in vitro and in vivo. Planta Med 2006, 72:1285-1289. 10.1055/s-2006-951680, 17022003.
35. Estrada AC, Syrovets T, Pitterle K, Lunov O, Buchele B, Schimana-Pfeifer J, Schmidt T, Morad SA, Simmet T. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells. Mol Pharmacol 2010, 77:378-387. 10.1124/mol.109.060475, 20018812.
36. Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988, 80:556-566. 10.1093/jnci/80.8.556, 3286879.
37. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000, 87:227-253. 10.1016/S0163-7258(00)00086-3, 11008002.
38. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229. 10.1124/pr.56.2.6, 15169927.
39. Frank MB, Yang Q, Osban J, Azzarello JT, Saban MR, Saban R, Ashley RA, Welter JC, Fung KM, Lin HK. Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity. BMC Complement Altern Med 2009, 9:6. 10.1186/1472-6882-9-6, 2664784, 19296830.
40. Ofir R, Seidman R, Rabinski T, Krup M, Yavelsky V, Weinstein Y, Wolfson M. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ 2002, 9:636-642. 10.1038/sj.cdd.4401012, 12032672.
41. Feng X, Wu Z, Wu Y, Hankey W, Prior TW, Li L, Ganju RK, Shen R, Zou X. Cdc25A regulates matrix metalloprotease 1 through Foxo1 and mediates metastasis of breast cancer cells. Mol Cell Biol 2011, 31:3457-3471. 10.1128/MCB.05523-11, 21670150.
42. Gozgit JM, Pentecost BT, Marconi SA, Otis CN, Wu C, Arcaro KF. Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer. Mol Cancer Res 2006, 4:905-913. 10.1158/1541-7786.MCR-06-0147, 17189381.
43. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004, 64:4302-4308. 10.1158/0008-5472.CAN-03-3958, 15205345.
44. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 1979, 5:1225-1230.
45. West GW, Weichselbaum R, Little JB. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 1980, 40:3665-3668.
46. Lin HJ, Hsieh FC, Song H, Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 2005, 93:1372-1381. 10.1038/sj.bjc.6602862, 2361529, 16288304.
47. Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Kung W, Wight E, Mayhew M, Eppenberger U, Eppenberger-Castori S. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 2005, 7:R394-401. 10.1186/bcr1015, 1175052, 15987444.
48. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002, 86:540-545. 10.1038/sj.bjc.6600126, 2375266, 11870534.
49. Svensson S, Jirstrom K, Ryden L, Roos G, Emdin S, Ostrowski MC, Landberg G. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005, 24:4370-4379. 10.1038/sj.onc.1208626, 15806151.
50. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001, 95:247-254. 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S, 11400118.
51. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 2005, 12:599-614. 10.1677/erc.1.00946, 16172194.
52. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 2006, 66:5950-5959. 10.1158/0008-5472.CAN-05-3243, 16740736.
53. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007, 18:1323-1328. 10.1093/annonc/mdm170, 17693645.
54. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004, 10:8059-8067. 10.1158/1078-0432.CCR-04-0035, 15585641.
55. Lev DC, Kim LS, Melnikova V, Ruiz M, Ananthaswamy HN, Price JE. Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. Br J Cancer 2004, 91:795-802. 2364773, 15280923.
56. Liu JJ, Duan RD. LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells. Anticancer Res 2009, 29:2987-2991.
57. Altmann A, Fischer L, Schubert-Zsilavecz M, Steinhilber D, Werz O. Boswellic acids activate p42MAPK and p38 MAPK and stimulate Ca2+ mobilization. Biochem Biophys Res Commun 2002, 290:185-190. 10.1006/bbrc.2001.6153, 11779151.
58. Poeckel D, Tausch L, Altmann A, Feisst C, Klinkhardt U, Graff J, Harder S, Werz O. Induction of central signalling pathways and select functional effects in human platelets by β-boswellic acid. Br J Pharmacol 2005, 146:514-524. 10.1038/sj.bjp.0706366, 1751190, 16086030.
59. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994, 54:1812-1817.
60. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995, 10:775-778.
61. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994, 57:353-361. 10.1002/ijc.2910570311, 8168995.
62. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996, 69:92-99. 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q, 8608989.
63. Samady L, Dennis J, Budhram-Mahadeo V, Latchman DS. Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor. Cancer Biol Ther 2004, 3:317-323. 10.4161/cbt.3.3.698, 14726699.
64. An HX, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999, 154:113-118. 10.1016/S0002-9440(10)65257-1, 1868599, 9916925.
65. Takano Y, Takenaka H, Kato Y, Masuda M, Mikami T, Saegusa M, Okayasu I. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity. J Cancer Res Clin Oncol 1999, 125:505-512. 10.1007/s004320050309, 10480344.
66. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y, Gardner H, Kiyokawa H, Harris LN, Stal O, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006, 9:23-32. 10.1016/j.ccr.2005.12.012, 16413469.
67. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010, 29:4018-4032. 10.1038/onc.2010.154, 20473330.
68. Liu JJ, Huang B, Hooi SC. Acetyl-keto-β-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells. Br J Pharmacol 2006, 148:1099-1107. 10.1038/sj.bjp.0706817, 1752013, 16783403.
69. Glaser T, Winter S, Groscurth P, Safayhi H, Sailer ER, Ammon HP, Schabet M, Weller M. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer 1999, 80:756-765. 10.1038/sj.bjc.6690419, 2362292, 10360653.
70. Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, Chattopadhyay A, Gm A, Navab M, Fogelman AM, et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the anti-oxidant enzyme MnSOD. Int J Cancer 2011,
71. Dozio E, Ruscica M, Passafaro L, Dogliotti G, Steffani L, Marthyn P, Pagani A, Demartini G, Esposti D, Fraschini F, et al. The natural antioxidant α-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells. Eur J Pharmacol 2010, 641:29-34. 10.1016/j.ejphar.2010.05.009, 20580704.